Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 16/20 | 0.39 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.38 |
| ▸ | CDK2 | P24941 | 2/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.37 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 8/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.35 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4112834 | 0.94 | ADORA2A (0.40) | ADORA2ACCNE2CCNE1CDK2CCNA2 | |
| SCHEMBL4111505 | 0.92 | ADORA2A (0.42) | ADORA2ACCNE2CCNE1CDK2CCNA2 | |
| SCHEMBL244005 | 0.92 | CCNE2 (0.38) | ADORA2ACCNE2CCNE1CDK2ADORA3 | |
| SCHEMBL4110918 | 0.88 | ADORA2A (0.37) | ADORA2ACCNE2CCNE1CDK2ADORA3 | |
| SCHEMBL4122717 | 0.87 | ADORA2A (0.39) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL243678 | 0.86 | ADORA2A (0.43) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL1412210 | 0.86 | ADORA2A (0.46) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL244571 | 0.86 | ADORA2A (0.42) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL1402098 | 0.85 | ADORA2A (0.47) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL1402023 | 0.85 | ADORA2A (0.38) | ADORA2ACCNE2CCNE1CDK2CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099214-A1 | Organic Compounds | NOVARTIS AG | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099214-A1 | Organic Compounds | CYP3A43, OXER1, OPRM1 | ADORA2A 2082/4885CCNE2 444/4885CCNE1 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.